💊
Acvybra
denosumab
Knochenabbau;Osteoporose;Osteoporose, postmenopausal
✅ Autorisiert
Biosimilar
✅
Keine aktiven Warnungen
Dieses Arzneimittel unterliegt derzeit keinen Lieferengpässen, Sicherheitshinweisen oder Rückrufen.
Wofür es verwendet wird
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Acvybra significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Acvybra significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
⚠️ Patientensicherheit
No
Offizielle EMA-Seite
https://www.ema.europa.eu/en/medicines/human/EPAR/acvybra